




UROLIFT[®]

BPH Relief. In Sight.[™]

OPEN UP TO A
PROVEN APPROACH TO BPH[™]

BPH is the Number One Reason Men Visit Urologists

Top 10 reasons for visits to urologists¹



1. IMS Health NDT Urology Specialty Profile,
July 2012 - June 2013

Redefining Minimally Invasive BPH Treatment



Watchful Waiting

34%

4.3 Million
Patients



Medical Therapy

64%

7.9 Million
Patients



Surgery/Procedure

2%

248,000
Patients

Each year, **16.3% or
2 Million** discontinue drugs
(inadequate relief, side effects, etc.)

The UroLift® System
is a proven option for patients
seeking an alternative to BPH medications

NeoTract US Market Model estimates for 2020 based
on IQVIA Health Drug and Procedure data.

Safe and Effective

Significant improvement without the significant permanent downsides of laser/TURP

UROLIFT[®]

Mild to Moderate AE's*¹ 0.7%

Stricture²

10.6-11.4

IPSS Improvement^{1,3}

1.9-2.3

QOL^{1,3}

Laser/TURP

7-10%

ED⁴

42-65%

EjD⁴

SUI's
Stricture⁴

1-3%
3-7%

14-15

IPSS Improvement⁴

1.7-3.3

QOL⁴

SUI – Stress Urinary Incontinence

EjD – Ejaculatory Dysfunction

ED – Erectile Dysfunction

QOL – Quality of Life


Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.¹ Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.

*No instances of new, sustained erectile or ejaculatory dysfunction in the LIFT pivotal study

1. Roehrborn, J Urol 2013; 2. Roehrborn, Urol Practice 2015;
3. Sonksen, Eur Urol 2015; 4. Cindolo et al. Int Urol Nephrol 2017;
5. Noordhoff et al. Neurourol Urodyn 2019;
6. AUA/BPH Guidelines 2003, 2010

Safe and Effective

Benefits and side effects of BPH medications:
comparison of outcomes at 1-2 years




ED – Erectile Dysfunction EjD – Ejaculatory Dysfunction QOL – Quality of Life

6. AUA BPH Guidelines 2003, 2010; 7. Jan Taper, Cent Eur J Urol 2011; 8. Trish, J Sex Med 2015; 9. Marhart et al. Rev Urol 2005

AUA BPH Guidelines Recognize the Need for Earlier Intervention

From healthy bladder to permanent damage



Healthy Bladder



Bladder Worsens



Permanently Damaged

"Since many men discontinue medical therapy, yet proportionately few seek surgery, there is a large clinical need for an effective treatment that is less invasive than surgery. With this treatment class, perhaps a significant portion of men with BOO who have stopped medical therapy can be treated prior to impending bladder dysfunction.¹"

The UroLift® System Procedure: Now Part of the Standard of Care

AUA BPH Guideline highlights

- ✓ Urologists should consider **Prostatic Urethral Lift (PUL)**, (using the UroLift® System) for the treatment of men with BPH.
- ✓ Patients “should be made aware that surgical treatment can cause ejaculatory dysfunction (EjD) and may worsen ED.”
- ✓ “In men so concerned about new onset of ED and/or EjD, PUL likely does not pose additional risk.”



To review the guidelines, visit auanet.org

Click on Education > Guidelines and Policies >
Benign Prostatic Hyperplasia (BPH)

The UroLift[®] System Procedure

Patients have been shown to have a better recovery experience than TURP, with durable results and no new and lasting sexual dysfunction^{*1-7}

- ✓ **Rapid** relief and recovery in days, not months^{1,8}
- ✓ **Lowest** catheter rate of the leading BPH procedures⁸
- ✓ The **only** leading BPH procedure that does not destroy tissue
- ✓ Proven **durability** through five years⁹
- ✓ **Real world** outcomes largely consistent with randomized controlled data¹⁰



^{*}No instances of new, sustained erectile or ejaculatory dysfunction in the LLET, pivotal study

1. Roehrborn, Can J Urol 2015; 2. Roehrborn, J Urology 2013;

3. AUA BPH Guidelines 2003, 2010, 2018 amended 2019; 4. Naspro, Eur Urol 2009;

5. Montorsi, J Urol 2008; 6. McVary, J Sex Med 2016; 7. Sonksen Eur Urol 2015;

8. Shore Can J Urol 2014; 9. Roehrborn et al. Can J Urol 2017;

10. Bure et al J Endourol 2019

Straightforward Approach

Mechanical solution to a mechanical problem

The UroLift® Delivery Device is inserted transurethraly through a rigid sheath under cystoscopic visualization in order to reach the targeted area of obstruction.

The obstructing prostatic lobes are retracted by small permanent UroLift Implants which are deployed via a needle that comes out of the delivery device.

Each UroLift Delivery Device contains one UroLift Implant. Typically four to six implants are placed into the prostate.¹



UroLift® Permanent Implant

1. Roehrborn, J Urology 2013 LIFT Study

Broad Spectrum of BPH Anatomies Treated

98% Of the BPH patient population are eligible¹⁻⁴




No Visible
Median Lobe



Obstructive or Protruding
Median Lobe



Pre-procedure



Post-procedure


Individual results may vary

Indicated for men with prostate sizes up to 100cc,
including lateral and median lobe hyperplasia

1. Edhards, Neurourol and Urodynamics 2001;
2. Kaplan, J Urol 2011; 3. McVary, J Sex Med 2014;
4. Roehrborn, J Urol 2013

Reproducible Durable Results

Across multiple studies and in the real world¹



- ✓ Rapid symptom relief and recovery^{2,3}
- ✓ AUASI improvement of 47% at 1 year² and sustained at 36% at 5 years⁴
- ✓ Sustained QOL improvements from 1 year (51%)² to 5 years (50%)⁴
- ✓ Qmax improvement of 59% at 1 year² and sustained at 44% at 5 years⁴
- ✓ No (0%) incidence of de novo sustained ejaculatory or erectile dysfunction^{*2}
- ✓ Low surgical retreatment rate of 5% at 1 year² and 13.6% at 5 years⁴

*No instances of new sustained erectile or ejaculatory dysfunction in the LIFT pivotal study

1. Eurs et al | Endourol 2019; 2. Roehrborn, J Urology 2013;
3. Shore, Can J Urol 2014; 4. Roehrborn et al, Can J Urol 2017

UROLIFT®

"The procedure has allowed me to regain my quality of life. I have no urgency, no frequency and I'm thoroughly satisfied with the results."

STEPHEN RICHARDSON, MD (patient)

"It is our responsibility to educate the patient about all the options. Many of my patients prefer the UroLift® System procedure over a pill."

DR. ROBERT COWLES†

"It's just a friendlier option for the patient – they recover quickly and get on with their life."

DR. STEVEN GANGE†

"I can genuinely say the benefits of the UroLift System are real and the procedure and recovery were easy to tolerate."

DR. EDWARD COHEN†

†Drs. Robert Cowles, Steven Gange, and Edward Cohen are paid consultants of NeoTract | Teleflex Interventional Urology.

Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.¹ Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.

1. Roehrborn, J Urology 2013 LIFT Study

FIND US AT | FOR MORE INFORMATION

@UroLift 

Visit www.UroLift.com

facebook.com/UroLift 

Customer Service: **877.408.9628** (toll-free)

Search UroLift on YouTube 

Reimbursement Resource Center: **844.516.5966** (toll-free)


NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is to improve the standard of care for patients with Benign Prostatic Hyperplasia (BPH), a broadly underserved market. Our first product is the UroLift® System, a minimally invasive device designed to treat lower urinary tract symptoms (LUTS) due to BPH.

neotract® | Teleflex®

INTERVENTIONAL UROLOGY

Pleasanton, CA 94588

Tel: 925.401.0700 • 877.408.9628

Teleflex, the Teleflex logo, NeoTract, the NeoTract logo, UroLift, and  are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2020 NeoTract, Inc. All rights reserved. Printed in the USA.

MAC00034-01 Rev G